|1.||Nemes, L: 2 articles (09/2015 - 07/2009)|
|2.||Rusen, L: 2 articles (09/2015 - 09/2010)|
|3.||Roth, D A: 2 articles (09/2010 - 07/2009)|
|4.||Arkin, S: 2 articles (09/2010 - 07/2009)|
|5.||Udata, C: 2 articles (07/2009 - 03/2007)|
|6.||Négrier, C: 2 articles (07/2007 - 09/2004)|
|7.||Stieltjes, N: 2 articles (07/2007 - 09/2004)|
|8.||Lenk, H: 2 articles (03/2007 - 09/2003)|
|9.||Mannucci, P M: 2 articles (03/2007 - 11/2003)|
|10.||Pollmann, H: 2 articles (03/2007 - 03/2007)|
|1.||Hemophilia A (Haemophilia)
06/01/2002 - "These data predict that ReFacto will be effective in correcting human factor VIII deficiency states."
09/01/2005 - "A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A."
06/01/2002 - "Preclinical studies of ReFacto have focused on efficacy of the product for the hemophilia A patient population. "
09/01/2005 - "This clinical trial evaluated the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with severe or moderately severe haemophilia A over a period of 6 months or 50 exposure days (EDs), whichever occurred first. "
09/01/2010 - "BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study."
03/01/2007 - "Overall, most physicians (41/43 [95.3%]) were 'very satisfied' or 'satisfied' with the efficacy of REFACTO in the treatment of bleeding episodes. "
01/01/2009 - "A median of four bleeding episodes occurred during the 24-month study period, and 93% of the episodes were resolved with </=2 ReFacto infusions. "
01/01/2009 - "In conclusion, ReFacto demonstrated good safety and efficacy in prophylaxis as well as treatment of bleeding episodes."
01/01/2009 - "In the 7 on-demand patients, there was a median of 18 bleeding episodes, 87% of which resolved with </=2 ReFacto infusions. "
01/01/2009 - "Among patients on regular prophylaxis, 6 of the 30 patients (20%) receiving ReFacto experienced no bleeding episodes. "
|3.||Prion Diseases (Transmissible Spongiform Encephalopathies)
09/01/2007 - "While to date there have been no cases of transmissible spongiform encephalopathy (TSE) resulting from the clinical use of HSA, Wyeth conducted a study to demonstrate that the ReFacto manufacturing process has significant capacity to remove a TSE agent if it were present as a contaminant in the HSA. "
09/01/2007 - "Transmissible spongiform encephalopathy agent clearance by the immunoaffinity and anion-exchange chromatography steps of the ReFacto manufacturing process."
|1.||Prothrombin (Factor II)
|3.||recombinant FVIIa (rFVIIa)
|5.||Factor VIII (Coagulation Factor VIII)
|6.||von Willebrand Factor
|8.||recombinant factor VIII SQ
|9.||human F8 protein
|10.||7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)
|2.||Surgical Instruments (Clip)